Page 5 - Dr Reddy’s
How a change in proprietary strategy is yielding results for Dr Reddy's
As reduced commercialisation costs add to profitability, the growth in India and emerging markets is also encouraging
 "How a change in proprietary strategy is yielding results for Dr Reddy's")
Dr Reddy's sells US rights of branded neurology products to Upsher-Smith
The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act of the US government
 "Dr Reddy's sells US rights of branded neurology products to Upsher-Smith")
Dr Reddy's to sell rights of 2 neurology drugs to Upsher-Smith for $110 mn
Dr Reddy's said it will receive sales-based royalties on a quarterly basis
 "Dr Reddy's to sell rights of 2 neurology drugs to Upsher-Smith for $110 mn")
New plaque psoriasis drug study yields positive results: Dr Reddy's
The detailed safety and efficacy data from the study would be presented in future dermatology conferences
Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook
Lower traction in US sales, sequential decline in other key geographies and subdued margin gains disappointed the Street
 "Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook")
Dr Reddy's recalls anti-seizure drug in the US market
According to information posted on the US Food and Drug Administration(USFDA), the company initiated a voluntary recall of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April
 "Dr Reddy's recalls anti-seizure drug in the US market")
Dr Reddy's eyeing volume and value growth in the US
Firm is adding volume-driven products such as the recent acquisition of 42 ANDAs. The portfolio has over 30 injectables and an addressable market size of $645 mn
 "Dr Reddy's eyeing volume and value growth in the US")
Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US
The company said it has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products
 "Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US")
Focus on India, emerging markets could drive Dr Reddy's rerating
These markets get a higher valuation compared to the US
 "Focus on India, emerging markets could drive Dr Reddy's rerating")
Dr Reddy's may take six months to resolve issues flagged by US FDA
Compliance norms to keep Dr Reddy's under pressure
US insurer names Dr Reddy's, dozens of other drug firms in price fixing row
The complaint involves 30 generic drugs, 42 companies; DRL denies wrongdoing, says will vigorously defend itself
 "US insurer names Dr Reddy's, dozens of other drug firms in price fixing row")
Dr Reddy's Q3 net profit up 45% at Rs 485 crore on lower tax outgo
It may be recalled that the company's net profit had declined 29 per cent in the year ago period
Dr Reddy's launches injection for anesthesia and sedation in US market
Dr Reddy's said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse
 "Dr Reddy's launches injection for anesthesia and sedation in US market")
Dr. Reddy's retreats from record after earnings
Dr. Reddy's retreats from record after earnings
Dr Reddy's launches anti-coagulant, dipyridamole drugs in US market
Quoting IMS Health data, Dr Reddy's Laboratories said the Aggrenox brand and generic had US sales of approximately $182 million for the most recent 12 months ending in October 2018
 "Dr Reddy's launches anti-coagulant, dipyridamole drugs in US market")
Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market
Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE
 "Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market")
Dr Reddy's Labs hits 52-week high; stock rallies 5% in two days
The stock hit a 52-week high of Rs 2,700, up 2%, extending its previous day's 3% gain on the BSE, surpassed its previous high of Rs 2,687 recorded on September 28 in intra-day trade.
 "Dr Reddy's Labs hits 52-week high; stock rallies 5% in two days")
Dr Reddy's launches blood pressure drug chlorthalidone tablets in US mar
Chlorthalidone tablets USP in the strengths of 25 mg and 50 mg
Shot in the arm for Dr Reddy's outlook as court clears block on US generic
The stock of Dr Reddy's Laboratories was up about six per cent on the bourses, after an appellate court in the US on Tuesday cleared the way for the company to resume sales of a Suboxone generic. The drug is used to treat opioid addiction and is expected to generate as much as $100 million (a little over Rs 7 billion) in revenue annually.Dr Reddy's had stopped selling the drug after a lower court gave an adverse verdict in June. Prior to the restraining order, the company had reportedly earned $25 mn from the drug, which has an overall market size pegged at $1.8 bn. The development comes as a shot in the arm for Dr Reddy's, which has been struggling to retain its sales growth in the US market, due to fewer big-ticket launches and delayed product approvals. Analysts termed the development a big positive but noted a multiple player market could impact the company's share. Mylan has already settled with Indivior (the innovator) and is expected to soon enter with its own generic version ..
 "Shot in the arm for Dr Reddy's outlook as court clears block on US generic")
US FDA completes audit of Dr Reddy's Srikakulum plant; stock rises
Shares of Dr.Redyy's closed at Rs 2,470.85 a unit, up by 0.36 per cent compared to the previous close, at BSE on Friday
